Cargando…

COVID-19 patients may become predisposed to pulmonary arterial hypertension

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is causing the current pandemic of coronavirus disease 2019 (COVID-19) that have killed over one million people worldwide so far. To date, over forty million people have officially been identified to be infected with this virus with less t...

Descripción completa

Detalles Bibliográficos
Autores principales: Suzuki, Yuichiro J., Nikolaienko, Sofia I., Shults, Nataliia V., Gychka, Sergiy G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7787059/
https://www.ncbi.nlm.nih.gov/pubmed/33444904
http://dx.doi.org/10.1016/j.mehy.2021.110483
_version_ 1783632753978245120
author Suzuki, Yuichiro J.
Nikolaienko, Sofia I.
Shults, Nataliia V.
Gychka, Sergiy G.
author_facet Suzuki, Yuichiro J.
Nikolaienko, Sofia I.
Shults, Nataliia V.
Gychka, Sergiy G.
author_sort Suzuki, Yuichiro J.
collection PubMed
description Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is causing the current pandemic of coronavirus disease 2019 (COVID-19) that have killed over one million people worldwide so far. To date, over forty million people have officially been identified to be infected with this virus with less than 3% death rate. Since many more people are expected to have been infected with this virus without the official diagnosis, the number of people who have recovered from the SARS-CoV-2 infection should be substantial. Given the large number of people recovered from either the mild SARS-CoV-2 infection or more severe COVID-19 conditions, it is critical to understand the long-term consequences of the infection by this virus. Our histological evaluations revealed that patients died of COVID-19 exhibited thickened pulmonary vascular walls, one important hallmark of pulmonary arterial hypertension (PAH). By contrast, such pulmonary vascular remodeling lesions were not found in patients died of SARS-CoV-1 during the 2002–2004 SARS outbreak or due to the infection by H1N1 influenza. The advancement in the treatment for the human immunodeficiency virus (HIV) infection has been remarkable that HIV-infected individuals now live for a long time, in turn revealing that these individuals become susceptible to developing PAH, a fatal condition. We herein hypothesize that SARS-CoV-2 is another virus that is capable to triggering the increased susceptibility of infected individuals to developing PAH in the future. Given the large number of people being infected with SARS-CoV-2 during this pandemic and that most people recover from severe, mild or asymptomatic conditions, it is imperative to generate scientific information on how the health of recovered individuals may be affected long-term. PAH is one lethal consequence that should be considered and needs to be monitored. This may also foster the research on developing therapeutic agents to prevent PAH, which has not so far been successful.
format Online
Article
Text
id pubmed-7787059
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Author(s). Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-77870592021-01-06 COVID-19 patients may become predisposed to pulmonary arterial hypertension Suzuki, Yuichiro J. Nikolaienko, Sofia I. Shults, Nataliia V. Gychka, Sergiy G. Med Hypotheses Article Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is causing the current pandemic of coronavirus disease 2019 (COVID-19) that have killed over one million people worldwide so far. To date, over forty million people have officially been identified to be infected with this virus with less than 3% death rate. Since many more people are expected to have been infected with this virus without the official diagnosis, the number of people who have recovered from the SARS-CoV-2 infection should be substantial. Given the large number of people recovered from either the mild SARS-CoV-2 infection or more severe COVID-19 conditions, it is critical to understand the long-term consequences of the infection by this virus. Our histological evaluations revealed that patients died of COVID-19 exhibited thickened pulmonary vascular walls, one important hallmark of pulmonary arterial hypertension (PAH). By contrast, such pulmonary vascular remodeling lesions were not found in patients died of SARS-CoV-1 during the 2002–2004 SARS outbreak or due to the infection by H1N1 influenza. The advancement in the treatment for the human immunodeficiency virus (HIV) infection has been remarkable that HIV-infected individuals now live for a long time, in turn revealing that these individuals become susceptible to developing PAH, a fatal condition. We herein hypothesize that SARS-CoV-2 is another virus that is capable to triggering the increased susceptibility of infected individuals to developing PAH in the future. Given the large number of people being infected with SARS-CoV-2 during this pandemic and that most people recover from severe, mild or asymptomatic conditions, it is imperative to generate scientific information on how the health of recovered individuals may be affected long-term. PAH is one lethal consequence that should be considered and needs to be monitored. This may also foster the research on developing therapeutic agents to prevent PAH, which has not so far been successful. The Author(s). Published by Elsevier Ltd. 2021-02 2021-01-06 /pmc/articles/PMC7787059/ /pubmed/33444904 http://dx.doi.org/10.1016/j.mehy.2021.110483 Text en © 2021 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Suzuki, Yuichiro J.
Nikolaienko, Sofia I.
Shults, Nataliia V.
Gychka, Sergiy G.
COVID-19 patients may become predisposed to pulmonary arterial hypertension
title COVID-19 patients may become predisposed to pulmonary arterial hypertension
title_full COVID-19 patients may become predisposed to pulmonary arterial hypertension
title_fullStr COVID-19 patients may become predisposed to pulmonary arterial hypertension
title_full_unstemmed COVID-19 patients may become predisposed to pulmonary arterial hypertension
title_short COVID-19 patients may become predisposed to pulmonary arterial hypertension
title_sort covid-19 patients may become predisposed to pulmonary arterial hypertension
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7787059/
https://www.ncbi.nlm.nih.gov/pubmed/33444904
http://dx.doi.org/10.1016/j.mehy.2021.110483
work_keys_str_mv AT suzukiyuichiroj covid19patientsmaybecomepredisposedtopulmonaryarterialhypertension
AT nikolaienkosofiai covid19patientsmaybecomepredisposedtopulmonaryarterialhypertension
AT shultsnataliiav covid19patientsmaybecomepredisposedtopulmonaryarterialhypertension
AT gychkasergiyg covid19patientsmaybecomepredisposedtopulmonaryarterialhypertension